Security key
29337E102
Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN)
CUSIP: 29337E102
Q2 2023 13F Holders as of 30 Jun 2023
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Shares outstanding
- 59,773,132
- Total 13F shares
- 39,092,843
- Share change
- +5,535,094
- Total reported value
- $797,915,923
- Put/Call ratio
- 0%
- Price per share
- $20.41
- Number of holders
- 61
- Value change
- +$112,876,379
- Number of buys
- 43
- Number of sells
- 16
Report period
Q2 2023
Institutions
61
Top holders
10
ELVN full security history
Newer quarter: Q3 2023
Previous quarter: Q1 2023
Enliven Therapeutics, Inc. SEC filings
Enliven Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 29337E102
Recent filing periods:
Top shareholders of ELVN - Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
|
Company |
15%
|
8,996,213
|
$197,017,065 | — | 31 Mar 2023 | |
| 5AM Venture Management, LLC |
13F
|
Company |
9.7%
|
5,798,475
|
$126,986,603 | — | 31 Mar 2023 | |
| FMR LLC |
13F
|
Company |
5.3%
|
3,163,482
|
$69,280,255 | — | 31 Mar 2023 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
3.8%
|
2,296,210
|
$50,286,999 | — | 31 Mar 2023 | |
| Venrock Adviser, LLC |
13F
|
Company |
3.7%
|
2,214,142
|
$48,489,710 | — | 31 Mar 2023 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
3/4/5
|
Company · Former 10% owner |
3.6%
|
2,122,465
|
$46,481,984 | — | 31 Mar 2023 | |
| Cormorant Asset Management, LP |
13F
|
Company |
3.2%
|
1,936,133
|
$42,401,000 | — | 31 Mar 2023 | |
| Fairmount Funds Management LLC |
13F
|
Company |
3.2%
|
1,924,938
|
$42,156,142 | — | 31 Mar 2023 | |
| Commodore Capital LP |
13F
3/4/5
|
Company · 10%+ Owner |
2.9%
|
1,731,365
|
$37,916,894 | — | 31 Mar 2023 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
1.4%
|
830,983
|
$18,198,528 | — | 31 Mar 2023 | |
| Boxer Capital, LLC |
13F
|
Company |
1.2%
|
710,644
|
$15,563,000 | — | 31 Mar 2023 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
1%
|
602,154
|
$13,183,336 | — | 31 Mar 2023 | |
| Logos Global Management LP |
13F
|
Company |
0.67%
|
401,229
|
$8,786,915 | — | 31 Mar 2023 | |
| BML Capital Management, LLC |
13F
|
Company |
0.35%
|
212,179
|
$4,646,720 | — | 31 Mar 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.25%
|
151,914
|
$3,326,917 | — | 31 Mar 2023 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.12%
|
70,258
|
$1,539,000 | — | 31 Mar 2023 | |
| JBF Capital, Inc. |
13F
|
Company |
0.08%
|
50,050
|
$1,096,095 | — | 31 Mar 2023 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.08%
|
46,874
|
$1,027,000 | — | 31 Mar 2023 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.07%
|
41,411
|
$906,901 | — | 31 Mar 2023 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.06%
|
35,388
|
$774,997 | — | 31 Mar 2023 | |
| PRELUDE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.06%
|
34,062
|
$39,989 | — | 31 Mar 2023 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.06%
|
33,795
|
$740,110 | — | 31 Mar 2023 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.05%
|
30,979
|
$678,440 | — | 31 Mar 2023 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.03%
|
18,444
|
$403,924 | — | 31 Mar 2023 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.03%
|
17,950
|
$393,105 | — | 31 Mar 2023 | |
| MORGAN STANLEY |
13F
|
Company |
0.03%
|
17,418
|
$381,454 | — | 31 Mar 2023 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.03%
|
17,167
|
$375,957 | — | 31 Mar 2023 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.03%
|
15,295
|
$334,961 | — | 31 Mar 2023 | |
| MIRABELLA FINANCIAL SERVICES LLP |
13F
|
Company |
0.02%
|
11,670
|
$255,573 | — | 31 Mar 2023 | |
| CITIGROUP INC |
13F
|
Company |
0.02%
|
11,263
|
$246,660 | — | 31 Mar 2023 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.02%
|
9,915
|
$217,138 | — | 31 Mar 2023 | |
| STATE STREET CORP |
13F
|
Company |
0.02%
|
9,424
|
$206,386 | — | 31 Mar 2023 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.02%
|
8,986
|
$196,793 | — | 31 Mar 2023 | |
| BARCLAYS PLC |
13F
|
Company |
0.01%
|
7,227
|
$158,271 | — | 31 Mar 2023 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.01%
|
6,545
|
$143,335 | — | 31 Mar 2023 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
1,657
|
$36,000 | — | 31 Mar 2023 | |
| Dorsey Wright & Associates |
13F
|
Company |
0%
|
1,237
|
$27,090 | — | 31 Mar 2023 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0%
|
746
|
$16,337 | — | 31 Mar 2023 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0%
|
486
|
$11,000 | — | 31 Mar 2023 | |
| UBS Group AG |
13F
|
Company |
0%
|
334
|
$7,315 | — | 31 Mar 2023 | |
| Middle East Fze Point72 |
13F
|
Individual |
0%
|
293
|
$6,417 | — | 31 Mar 2023 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0%
|
243
|
$5,322 | — | 31 Mar 2023 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
94
|
$2,000 | — | 31 Mar 2023 | |
| Mariner Managed Account Solutions, LLC |
13F
|
Company |
0%
|
50
|
$1,095 | — | 31 Mar 2023 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
24
|
$526 | — | 31 Mar 2023 | |
| David P. Bonita |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
4,207,568
mixed-class rows
|
$63,552,894 | — | 02 Jun 2022 | |
| New Enterprise Associates 14, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,611,050
|
$39,518,242 | — | 05 Apr 2022 | |
| Braden M. Leonard |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,997,774
|
$30,236,309 | — | 03 Jan 2023 | |
| Andrew J. Schwab |
3/4/5
|
Director, 10%+ Owner |
—
class O/S missing
|
27,567
|
— | — | 23 Feb 2023 | |
| Mark Chin |
3/4/5
|
Director |
—
mixed-class rows
|
2,352,572
mixed-class rows
|
$35,477,530 | — | 02 Jun 2022 |
Institutional Holders of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) as of Q2 2023
As of 30 Jun 2023,
Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) was held by
61 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
39,092,843 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, 5AM Venture Management, LLC, FMR LLC, COMMODORE CAPITAL LP, CITADEL ADVISORS LLC, VR Adviser, LLC, Fairmount Funds Management LLC, RA CAPITAL MANAGEMENT, L.P., Cormorant Asset Management, LP, and BlackRock Inc..
This page lists
61
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2023 vs Q1 2023 Across Filers
Q1 2023 holders
44
Q2 2023 holders
61
Holder diff
17
| Investor | Q1 2023 Shares | Q2 2023 Shares | Share Diff | Share Chg % | Q1 2023 Value $ | Q2 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.